<code id='F70E8D1733'></code><style id='F70E8D1733'></style>
    • <acronym id='F70E8D1733'></acronym>
      <center id='F70E8D1733'><center id='F70E8D1733'><tfoot id='F70E8D1733'></tfoot></center><abbr id='F70E8D1733'><dir id='F70E8D1733'><tfoot id='F70E8D1733'></tfoot><noframes id='F70E8D1733'>

    • <optgroup id='F70E8D1733'><strike id='F70E8D1733'><sup id='F70E8D1733'></sup></strike><code id='F70E8D1733'></code></optgroup>
        1. <b id='F70E8D1733'><label id='F70E8D1733'><select id='F70E8D1733'><dt id='F70E8D1733'><span id='F70E8D1733'></span></dt></select></label></b><u id='F70E8D1733'></u>
          <i id='F70E8D1733'><strike id='F70E8D1733'><tt id='F70E8D1733'><pre id='F70E8D1733'></pre></tt></strike></i>

          Home / fashion / entertainment

          entertainment


          entertainment

          author:explore    Page View:494
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In